Prognostic Value of Interim SPECT/CT in Prostate Cancer Therapy: Meta-Analysis

Seven studies with 648 patients were included in this systematic review and meta-analysis. It evaluates the prognostic value of interim post-treatment SPECT/CT parameters for survival outcomes in metastatic castration-resistant prostate cancer patients receiving lutetium-177-PSMA therapy. The dataset was authored by Amirreza Shamshirgaran and published on figshare in April 2026.

Use Cases

• Validate imaging biomarkers for early response assessment based on the analysis of new lesions and total tumor volume.
• Inform clinical trial design for prostate cancer therapies based on pooled hazard ratios for survival outcomes.
• Support the development of standardized radiologic monitoring protocols based on the review of SPECT/CT imaging parameters.

Strengths

• Includes pooled hazard ratios from seven studies with confidence intervals and p-values.
• Assessed study quality using the Oxford CEBM tool and evaluated publication bias.
• Focuses on a specific clinical question with a defined PICO framework and PRISMA guidelines.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is a 15.1 KB document, suggesting limited scope beyond the meta-analysis summary.

Provenance

Source

figshare

Collection Method

Systematic review and meta-analysis following PRISMA guidelines, searching PubMed/MEDLINE, Scopus, and Google Scholar.

Time Range

Studies searched up to December 2025.

Freshness

Last updated 2026-04-24 04:21:34; freshness should be verified.